Medical Device Law Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Device Law Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Archemix Corp.
Archemix Initiates Phase 2a for Lead Aptamer Product Candidate ARC1779
April 19th, 2009
Archemix Corp., a privately-held biotechnology company working to develop aptamer-based therapeutics, announced that it has initiated a Phase 2a clinical trial of its novel anti-von Willebrand Factor (VWF) aptamer, ARC1779. The trial is designed to evaluate the safety and efficacy of ARC1779 as a potential first-in-class anti-platelet agent in patients with carotid artery disease undergoing a surgical procedure known as carotid endarterectomy, or CEA. The recently initiated Phase 2a trial is a randomized, double-blind, placebo-controlled study to evaluate the efficacy, safety and tolerability of ARC1779 in approximately 100 CEA patients at multiple centers in North...
Source: Medical Device Law Weekly (2009-04-19)
|
